Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr;29(2):321-47.
doi: 10.1128/CMR.00068-15.

Fosfomycin

Matthew E Falagas  1 , Evridiki K Vouloumanou  2 , George Samonis  3 , Konstantinos Z Vardakas  4
Affiliations
Review

Fosfomycin

Matthew E Falagas et al. Clin Microbiol Rev. 2016 Apr.

Abstract

The treatment of bacterial infections suffers from two major problems: spread of multidrug-resistant (MDR) or extensively drug-resistant (XDR) pathogens and lack of development of new antibiotics active against such MDR and XDR bacteria. As a result, physicians have turned to older antibiotics, such as polymyxins, tetracyclines, and aminoglycosides. Lately, due to development of resistance to these agents, fosfomycin has gained attention, as it has remained active against both Gram-positive and Gram-negative MDR and XDR bacteria. New data of higher quality have become available, and several issues were clarified further. In this review, we summarize the available fosfomycin data regarding pharmacokinetic and pharmacodynamic properties, the in vitro activity against susceptible and antibiotic-resistant bacteria, mechanisms of resistance and development of resistance during treatment, synergy and antagonism with other antibiotics, clinical effectiveness, and adverse events. Issues that need to be studied further are also discussed.

PubMed Disclaimer

Figures

FIG 1
FIG 1
(A) Molecular structure of fosfomycin trometamol. (B) Molecular structure of fosfomycin calcium. (C) Molecular structure of fosfomycin disodium.
None
None
None
None
See this image and copyright information in PMC

References

    1. Hendlin D, Stapley EO, Jackson M, Wallick H, Miller AK, Wolf FJ, Miller TW, Chaiet L, Kahan FM, Foltz EL, Woodruff HB, Mata JM, Hernandez S, Mochales S. 1969. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science 166:122–123. doi: 10.1126/science.166.3901.122. - DOI - PubMed
    1. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. 2008. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 46:1069–1077. doi: 10.1086/527442. - DOI - PubMed
    1. Frimodt-Moller N. 2010. Fosfomycin, p 935–944. In Grayson ML. (ed), Kucers' The use of antibiotics, 6th ed Edward Arnold Ltd, London, United Kingdom.
    1. Paladin Labs. 2007. Monurol package insert. Paladin Labs, Quebec, Canada.
    1. Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, McKevitt M, Moorehead L, Montgomery AB, Geller DE. 2012. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Respir Crit Care Med 185:171–178. doi: 10.1164/rccm.201105-0924OC. - DOI - PMC - PubMed

MeSH terms